Search results for "hematology"

Seoul St. Mary’s Hospital Wins 8 of 30 Awards at ICBMT 2026, Claiming Top Honors for Second Consecutive Year

Seoul St. Mary’s Hospital Wins 8 of 30 Awards at ICBMT 2026, Claiming Top Honors for Second Consecutive Year

The Catholic University of Korea’s Seoul St. Mary’s Hospital announced on the 20th that faculty members at its Hematology Hospital won eight of the...
Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T) therapies, announced on June 15 that...
FDA Clears Trial for Next-Gen CAR-T Therapy That Creates Cancer-Fighting Cells Inside Patients

FDA Clears Trial for Next-Gen CAR-T Therapy That Creates Cancer-Fighting Cells Inside Patients

CAR-T therapy for blood cancers conventionally involves removing a patient’s immune cells, modifying them in a...
Surgery Is Just the First Step in Lung Cancer: Why EGFR Mutation Testing Matters

Surgery Is Just the First Step in Lung Cancer: Why EGFR Mutation Testing Matters

Lung cancer is the second most commonly diagnosed cancer in South Korea and the leading cause of cancer mortality,...
GC Cell Administers Experimental CAR-NK Therapy at Seoul National University Hospital Following MFDS Approval

GC Cell Administers Experimental CAR-NK Therapy at Seoul National University Hospital Following MFDS Approval

GC Cell announced on Sept. 18 that South Korea’s Ministry of Food and Drug Safety has approved the compassionate use of...
Over 65 and Shut Out of Stem Cell Transplants? Fitness, Not Age, Should Guide Multiple Myeloma Care

Over 65 and Shut Out of Stem Cell Transplants? Fitness, Not Age, Should Guide Multiple Myeloma Care

Older adults diagnosed with multiple myeloma should not automatically be ruled out for autologous hematopoietic stem...
South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

Curocell announced on Sept. 4 that its chimeric antigen receptor T-cell (CAR-T) therapy Rimqarto (generic name:...
Gachon University Gil Medical Center Expands Advanced Blood Cancer Care as Regional CAR-T Center Reaches Two-Year Milestone

Gachon University Gil Medical Center Expands Advanced Blood Cancer Care as Regional CAR-T Center Reaches Two-Year Milestone

For patients with aggressive blood cancers that recur or fail to respond to standard chemotherapy, chimeric antigen...
Can Daraxonrasib Reshape Pancreatic Cancer Care? Experts Weigh Promise and Limits

Can Daraxonrasib Reshape Pancreatic Cancer Care? Experts Weigh Promise and Limits

Pancreatic cancer remains one of the most formidable malignancies. Because early-stage disease rarely produces distinct...
Hanyang University Hospital Launches Dedicated Cancer Hospital, Aiming for One-Week Diagnosis-to-Surgery Window

Hanyang University Hospital Launches Dedicated Cancer Hospital, Aiming for One-Week Diagnosis-to-Surgery Window

Hanyang University Hospital is reorganizing the cancer center it has operated for 35 years into Hanyang University...